Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5271377
Max Phase: Preclinical
Molecular Formula: C49H86O15
Molecular Weight: 915.21
Associated Items:
ID: ALA5271377
Max Phase: Preclinical
Molecular Formula: C49H86O15
Molecular Weight: 915.21
Associated Items:
Canonical SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H](O)[C@H]1O
Standard InChI: InChI=1S/C49H86O15/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-41(52)62-37(34-59-40(51)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2)35-60-48-47(58)45(56)43(54)39(64-48)36-61-49-46(57)44(55)42(53)38(33-50)63-49/h5,7,11,13,17-18,37-39,42-50,53-58H,3-4,6,8-10,12,14-16,19-36H2,1-2H3/b7-5-,13-11-,18-17-/t37-,38-,39-,42+,43+,44+,45+,46-,47-,48-,49+/m1/s1
Standard InChI Key: WVWINZZVFAFVMJ-GDVDIDQFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 915.21 | Molecular Weight (Monoisotopic): 914.5967 | AlogP: 6.15 | #Rotatable Bonds: 37 |
Polar Surface Area: 231.13 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 7 |
#RO5 Violations: 4 | HBA (Lipinski): 15 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 11.91 | CX Basic pKa: | CX LogP: 8.26 | CX LogD: 8.26 |
Aromatic Rings: 0 | Heavy Atoms: 64 | QED Weighted: 0.02 | Np Likeness Score: 1.16 |
1. Govindarajan M.. (2018) Amphiphilic glycoconjugates as potential anti-cancer chemotherapeutics., 143 [PMID:29126728] [10.1016/j.ejmech.2017.10.015] |
Source(1):